{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T07:23:28Z","timestamp":1786260208541,"version":"build-2736575974"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2017,12,19]],"date-time":"2017-12-19T00:00:00Z","timestamp":1513641600000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"The Bill and Melinda Gates foundation","doi-asserted-by":"crossref","award":["1106078"],"award-info":[{"award-number":["1106078"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12879-017-2885-8","type":"journal-article","created":{"date-parts":[[2017,12,19]],"date-time":"2017-12-19T05:18:21Z","timestamp":1513660701000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Delivery cost analysis of a reactive mass cholera vaccination campaign: a case study of Shanchol\u2122 vaccine use in Lake Chilwa, Malawi"],"prefix":"10.1186","volume":"17","author":[{"given":"Patrick G.","family":"Ilboudo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Bernard","family":"Le Gargasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,19]]},"reference":[{"key":"2885_CR1","unstructured":"WHO: Cholera vaccines: WHO position paper. In: Weekly Epidemiol Rec. 2010: 117\u2013128."},{"key":"2885_CR2","unstructured":"WHO: Prevention and control of cholera outbreaks: WHO policy and recommendations. Global Task Force on Cholera Control. In.; 2011."},{"key":"2885_CR3","first-page":"231","volume":"379","author":"J Clemens","year":"2014","unstructured":"Clemens J, Holmgren J. When, how, and where can oral cholera vaccines be used to interrupt cholera outbreaks? Curr Top Microbiol Immunol. 2014;379:231\u201358.","journal-title":"Curr Top Microbiol Immunol"},{"key":"2885_CR4","unstructured":"Nations Unies: Projet de document final du Sommet des Nations Unies consacr\u00e9 \u00e0 l\u2019adoption du programme de d\u00e9veloppement pour l\u2019apr\u00e8s-2015. In., vol. A\/69\/L.85: Nations Unies, Assembl\u00e9e g\u00e9n\u00e9rale; 2015."},{"issue":"6","key":"2885_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003832","volume":"9","author":"M Ali","year":"2015","unstructured":"Ali M, Nelson AR, Lopez AL, Sack DA. Updated global burden of cholera in endemic countries. PLoS Negl Trop Dis. 2015;9(6):e0003832.","journal-title":"PLoS Negl Trop Dis"},{"key":"2885_CR6","unstructured":"WHO\/UNICEF: Progress on Drinking Water and Sanitation: 2012 Update In Edited by Sanitation WUJMPfWSa; 2012."},{"key":"2885_CR7","unstructured":"WHO Prequalified Vaccines [\n                    https:\/\/extranet.who.int\/gavi\/PQ_Web\/\n                    \n                  ]."},{"issue":"10","key":"2885_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001289","volume":"5","author":"D Sur","year":"2011","unstructured":"Sur D, Kanungo S, Sah B, Manna B, Ali M, Paisley AM, Niyogi SK, Park JK, Sarkar B, Puri MK, et al. Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3 years of follow-up of a randomized, controlled trial. PLoS Negl Trop Dis. 2011;5(10):e1289.","journal-title":"PLoS Negl Trop Dis"},{"issue":"12","key":"2885_CR9","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/S1473-3099(13)70273-1","volume":"13","author":"SK Bhattacharya","year":"2013","unstructured":"Bhattacharya SK, Sur D, Ali M, Kanungo S, You YA, Manna B, Sah B, Niyogi SK, Park JK, Sarkar B, et al. 5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2013;13(12):1050\u20136.","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"2885_CR10","doi-asserted-by":"publisher","first-page":"881","DOI":"10.2471\/BLT.14.139949","volume":"92","author":"S Martin","year":"2014","unstructured":"Martin S, Lopez AL, Bellos A, Deen J, Ali M, Alberti K, Anh DD, Costa A, Grais RF, Legros D, et al. Post-licensure deployment of oral cholera vaccines: a systematic review. Bull World Health Organ. 2014;92(12):881\u201393.","journal-title":"Bull World Health Organ"},{"issue":"9","key":"2885_CR11","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1128\/CVI.00378-14","volume":"21","author":"S Kabir","year":"2014","unstructured":"Kabir S. Critical analysis of compositions and protective efficacies of oral killed cholera vaccines. Clinical and vaccine immunology : CVI. 2014;21(9):1195\u2013205.","journal-title":"Clinical and vaccine immunology : CVI"},{"issue":"48","key":"2885_CR12","doi-asserted-by":"publisher","first-page":"6878","DOI":"10.1016\/j.vaccine.2015.07.045","volume":"33","author":"M Ali","year":"2015","unstructured":"Ali M, You YA, Kanungo S, Manna B, Deen JL, Lopez AL, Wierzba TF, Bhattacharya SK, Sur D, Clemens JD. Assessing different measures of population-level vaccine protection using a case-control study. Vaccine. 2015;33(48):6878\u201383.","journal-title":"Vaccine"},{"issue":"3","key":"2885_CR13","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1080\/21645515.2016.1245250","volume":"13","author":"SN Desai","year":"2017","unstructured":"Desai SN, Pezzoli L, Alberti KP, Martin S, Costa A, Perea W, Legros D. Achievements and challenges for the use of killed oral cholera vaccines in the global stockpile era. Human vaccines & immunotherapeutics. 2017;13(3):579\u201387.","journal-title":"Human vaccines & immunotherapeutics"},{"issue":"12","key":"2885_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0005124","volume":"10","author":"V Mogasale","year":"2016","unstructured":"Mogasale V, Ramani E, Wee H, Kim JH. Oral cholera vaccination delivery cost in low- and middle-income countries: an analysis based on systematic review. PLoS Negl Trop Dis. 2016;10(12):e0005124.","journal-title":"PLoS Negl Trop Dis"},{"key":"2885_CR15","unstructured":"GeoHive - Malawi population statistics [\n                    http:\/\/www.nsomalawi.mw\/index.php?option=com_content&view=article&id=134%3Apopulationprojections-for-malawi&catid=8&Itemid=3\n                    \n                  ]."},{"issue":"2","key":"2885_CR16","first-page":"29","volume":"24","author":"A Khonje","year":"2012","unstructured":"Khonje A, Metcalf CA, Diggle E, Mlozowa D, Jere C, Akesson A, Corbet T, Chimanga Z. Cholera outbreak in districts around Lake Chilwa, Malawi: lessons learned. Malawi Med J. 2012;24(2):29\u201333.","journal-title":"Malawi Med J"},{"key":"2885_CR17","volume-title":"World health statistics 2016: monitoring health for the SDGs, sustainable development goals","author":"WHO","year":"2016","unstructured":"WHO. World health statistics 2016: monitoring health for the SDGs, sustainable development goals. Geneva, Switzerland: WHO; 2016."},{"key":"2885_CR18","unstructured":"IVI, WHO, DOVE: CHOLTOOL: Planning and costing. User's Guide, Seoul, South Korea. In. Seoul, South Korea; 2016."},{"key":"2885_CR19","unstructured":"19.-2016 OANDA [\n                    https:\/\/www.oanda.com\/lang\/fr\/\n                    \n                  ]."},{"key":"2885_CR20","unstructured":"World Economic Outlook Database, October 2016 [\n                    http:\/\/www.imf.org\/external\/pubs\/ft\/weo\/2016\/02\/weodata\/download.aspx\n                    \n                  ]."},{"issue":"9","key":"2885_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001512","volume":"10","author":"I Ciglenecki","year":"2013","unstructured":"Ciglenecki I, Sakoba K, Luquero FJ, Heile M, Itama C, Mengel M, Grais RF, Verhoustraeten F, Legros D. Feasibility of mass vaccination campaign with oral cholera vaccines in response to an outbreak in Guinea. PLoS Med. 2013;10(9):e1001512.","journal-title":"PLoS Med"},{"issue":"51","key":"2885_CR22","doi-asserted-by":"publisher","first-page":"6058","DOI":"10.1016\/j.vaccine.2013.10.021","volume":"31","author":"IA Khan","year":"2013","unstructured":"Khan IA, Saha A, Chowdhury F, Khan AI, Uddin MJ, Begum YA, Riaz BK, Islam S, Ali M, Luby SP, et al. Coverage and cost of a large oral cholera vaccination program in a high-risk cholera endemic urban population in Dhaka, Bangladesh. Vaccine. 2013;31(51):6058\u201364.","journal-title":"Vaccine"},{"issue":"2","key":"2885_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002629","volume":"8","author":"SK Kar","year":"2014","unstructured":"Kar SK, Sah B, Patnaik B, Kim YH, Kerketta AS, Shin S, Rath SB, Ali M, Mogasale V, Khuntia HK, et al. Mass vaccination with a new, less expensive oral cholera vaccine using public health infrastructure in India: the Odisha model. PLoS Negl Trop Dis. 2014;8(2):e2629.","journal-title":"PLoS Negl Trop Dis"},{"issue":"38","key":"2885_CR24","doi-asserted-by":"publisher","first-page":"4916","DOI":"10.1016\/j.vaccine.2015.07.042","volume":"33","author":"AR Sarker","year":"2015","unstructured":"Sarker AR, Islam Z, Khan IA, Saha A, Chowdhury F, Khan AI, Cravioto A, Clemens JD, Qadri F, Khan JA. Estimating the cost of cholera-vaccine delivery from the societal point of view: a case of introduction of cholera vaccine in Bangladesh. Vaccine. 2015;33(38):4916\u201321.","journal-title":"Vaccine"},{"issue":"51","key":"2885_CR25","doi-asserted-by":"publisher","first-page":"6706","DOI":"10.1016\/j.vaccine.2008.10.015","volume":"26","author":"P Lydon","year":"2008","unstructured":"Lydon P, Levine R, Makinen M, Brenzel L, Mitchell V, Milstien JB, Kamara L, Landry S. Introducing new vaccines in the poorest countries: what did we learn from the GAVI experience with financial sustainability? Vaccine. 2008;26(51):6706\u201316.","journal-title":"Vaccine"},{"issue":"10","key":"2885_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001844","volume":"6","author":"C Schaetti","year":"2012","unstructured":"Schaetti C, Weiss MG, Ali SM, Chaignat CL, Khatib AM, Reyburn R, Duintjer Tebbens RJ, Hutubessy R. Costs of illness due to cholera, costs of immunization and cost-effectiveness of an oral cholera mass vaccination campaign in Zanzibar. PLoS Negl Trop Dis. 2012;6(10):e1844.","journal-title":"PLoS Negl Trop Dis"},{"key":"2885_CR27","unstructured":"Nguyen A, Furrer E: GAVI Alliance Board: Vaccine introduction grants and operational support for campaigns. In.; 2012."},{"issue":"9","key":"2885_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0004072","volume":"9","author":"V Mogasale","year":"2015","unstructured":"Mogasale V, Kar SK, Kim JH, Mogasale VV, Kerketta AS, Patnaik B, Rath SB, Puri MK, You YA, Khuntia HK, et al. An estimation of private household costs to receive free oral cholera vaccine in Odisha, India. PLoS Negl Trop Dis. 2015;9(9):e0004072.","journal-title":"PLoS Negl Trop Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-017-2885-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-017-2885-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-017-2885-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T11:25:33Z","timestamp":1589455533000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-017-2885-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["2885"],"URL":"https:\/\/doi.org\/10.1186\/s12879-017-2885-8","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"10 May 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The overall study protocol received clearance from the National Health Sciences Research Committee (NHSRC) of the Ministry of Health in Malawi (approval number: NHSRC # 16\/3\/1559). The costing study was part of the cholera vaccination campaign monitoring and evaluation, which was approved by the MoH.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PGC and JBL work for AMP, which receives unrestricted funding from Sanofi Pasteur and grant-specific support from Crucell, Sanofi Pasteur, Pfizer, Merck, and GlaxoSmithKline.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"779"}}